Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Epilepsy 1Advanced Solid Tumors 1

Interventions

Sirolimus 4LY3295668 erbumine 3Everolimus 3Anticonvulsants 2perampanel 1clevidipine 1brivaracetam 1Vigabatrin 1Topotecan 1Therapeutic Touch 1Temozolomide 1TAS-119 1Sulfasalazine 1Sevoflurane 1Saline Solution 1Radiotherapy 1Propofol 1Paclitaxel 1Nitrous Oxide 1Midazolam 1Memantine 1Medical Marijuana 1Lidocaine 1Levetiracetam 1Ketamine 1Immunoglobulins, Intravenous 1Glycopyrrolate 1Gabapentin 1Fluid Therapy 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Epilepsy × TAS-119 × Clear all
NCT02134067 2024-09-05

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Terminated
30 enrolled

Epilepsy, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡